Kardigan (KARD) logo

Kardigan (KARD) stock

Cardiovascular medicines , market cap $1.2B

$11.54
-7.83%

Why is KARD down?

Down 26% from Nov 11 to Nov 20 while the S&P 500 fell 9%.

  • Its Nov 12 results: research and development expenses were $64.4M, from $49.1M a year before. It fell 10% on Nov 12.

Sources: Price history, Nov 20, 2026; Company release, Nov 12, 2026

−2Volatility moves 10.7% a day with no profit or positive free cash flow over four quarters on file

Tell me next time KARD moves

Free account, no card. An optional alert when KARD moves or its score changes.Pro, $1 for a first month. An optional alert when KARD moves or its score changes.Pro, 7 days free with a card. An optional alert when KARD moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on KARD →The other side, the timeline, and its peers, for Pro members.
Quality Score
-2
Poor
In its industry
#54of 89
Checks firing
0of 14
Choppy
From its high
-57.3%
under its best since listing

KARD's Quality Score fell 2 points on Fri, Nov 20, to -2. Trading went back to normal after a busy day (2 chart checks stopped).

New listing, trading since Jun 18, 2026. 109 trading days so far, so 3 of the 14 chart checks wait for more history.

Follow KARD's trial news. Pro members can get an alert when Kardigan files news, and see its trials, share raises, and its CEO's filings.

Get an alert when KARD files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ2 2027“Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027…”Trial data · SEC filing · Nov 12

Key facts on KARD

Key facts on KARD
Holding it backMoves 10.7% a day with no profit behind it
Latest filing8-K, Nov 12 Reported its quarterly results

KARD in the news

Thu Nov 12KARD: Kardigan Inc. filed SEC Form 8-K: Results of Operations and... quantisnow.com and 2 more · yesterday 7:06 AM ET KARD closed −9.9% that day.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

KARD catalysts

Coming up

After its last 2 reports it closed -2.6% on average, higher 1 of 2 times.

3 more coming up, with sizes and sources, for Pro members.

What's next for KARD, and how long its cash lasts

Next step the company has named

Q2 2027“Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts”Trial data · SEC filing · Nov 12

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
Danicamtiv · Symptomatic Genetic Dilated Cardiomyopathy · Phase 2/3
Its trial
KINSHIP-DCMPhase 2/3 · Recruiting · 332 people · main data estimated Sep 2027 · NCT07210723

3 more trials, 1 with data due this year, 1 more milestone and 5 filings, for Pro members.

Cash runway Sep 30 balance sheet

$591M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Paul L Berns bought 1,250,000 shares on Jun 22. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Anastasios Gianakakos’s 2 filings and quotes.

Get an alert when KARD files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How KARD ranks in Pharma

KARD is #54 of 89 by Quality Score.

How KARD ranks in Pharma
RankStockQuality Score
54Kardigan (KARD) logoKARDKardigan-2

More in Pharma

When does KARD report earnings, and what happens after?

Expected to report Tue Mar 23, before the open (in 122 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What KARD reported on Nov 12, 2026

The quarter

A loss of $0.64 a share, from $4.43.

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

KARD's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value
$1.2B
today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on KARD: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 2

+4.7%-9.9%
Aug 11Nov 12
ReportedGapReaction5
days
Nov 12, 2026Before open-1.7%-9.9%-21.4%
Aug 11, 2026Before open+1.4%+4.7%-2.5%

KARD closed higher after 1 of its last 2 reports.

Nothing is firing on KARD right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on KARD, and all 14 on every stock.Get in free →See the top 3 →Start Pro

KARD RSI on Nov 20: 35.8, below its 50-day average

Not scored

RSI 35.8, MACD below signal. Not scored.

3 more findings on KARD, each with its source, for Pro members.

KARD share count over time

Shares: 6.8 times the count a year ago (to Sep 30).

Shares of KARD outstanding, as filed
Shares
outstanding
As
of
93.6MNov 9, 2026
93.5MAug 7, 2026
Offerings, shelves, and splits of KARD, from its filings
From its
filings
Filed
Raised $400M in a sale of shares, about 34% of its market valueJun 18, 2026
Registered shares for sale (S-1)May 26, 2026

KARD's officers and directors

Officers and directors with a Form 4 in the last 12 months.

2 more officers and directors file at KARD.

See insider trades by person

Which ETFs hold KARD?

In ETFs: KARD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Kardigan

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

South San Francisco, CAkardigan.bio

Listed on Nasdaq on Jun 18, 2026, and is 28% below its $16 offer price now. Its IPO filing and first days

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on KARD and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn KARD's score around: 3 things
  • 5 more filings explained, a plain line each
  • Real-⁠time prices, no delay

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: KARD's Quality Score is -2 (Poor), #54 of 89 in Pharma.

What does KARD's Quality Score say?

KARD scores -2 today, which Breakaway calls Poor. It is #54 of 89 in Pharma by Quality Score, with 0 of 14 chart checks firing. Down 26% from Nov 11 to Nov 20 while the S&P 500 fell 9%. Shares: 6.8 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is KARD's Quality Score?

KARD scores -2 today, which Breakaway calls Poor (below zero). That is #54 of 89 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KARD's -2.

When does KARD report earnings?

Expected to report Tue Mar 23, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. KARD closed higher after 1 of its last 2 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Kardigan: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.